胰腺G3神经内分泌肿瘤切换生长抑素受体拮抗剂LM3后CAP-PRRT应答更优:个体内概念验证
本文报告一例67岁男性不可手术的转移性胰腺G3神经内分泌肿瘤,病灶在[68Ga]Ga-DOTATOC PET/CT上强阳性、在补充的[18F]-FDG PET/CT上仅弱阳性。经[177Lu]Lu-DOTA-奥曲肽PRRT长期反复治疗7年后仅达疾病稳定、无病灶部分退缩;换用生长抑素受体拮抗剂[177Lu]Lu-DOTA-LM3后观察到明显治疗应答,与紧接前177Lu-奥曲肽的稳定疾病效应形成鲜明对比。
要点
- 胰腺G3 NET病灶[68Ga]Ga-DOTATOC PET/CT强阳性、[18F]-FDG PET/CT仅弱阳性。
- [177Lu]Lu-DOTA-奥曲肽治疗7年后仅达疾病稳定,无病灶部分退缩。
- 换用[177Lu]Lu-DOTA-LM3后观察到明显治疗应答。
核心结论
- 本文认为生长抑素受体拮抗剂PRRT的疗效优于基于激动剂的PRRT。
研究设计与样本
- 本文为个体内概念验证,报告一例67岁男性不可手术的转移性胰腺G3神经内分泌肿瘤。
主要发现
- 病灶在[68Ga]Ga-DOTATOC PET/CT上强阳性,在补充的[18F]-FDG PET/CT上仅弱阳性。
- 经[177Lu]Lu-DOTA-奥曲肽PRRT长期反复治疗7年后仅达疾病稳定,无病灶部分退缩。
- 换用[177Lu]Lu-DOTA-LM3后观察到明显治疗应答,与紧接前177Lu-奥曲肽的稳定疾病效应形成鲜明对比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present a 67-year-old man with inoperable metastatic G3 NET of the pancreas. The lesions were intensely positive in [ 68 Ga]Ga-DOTATOC PET/CT and only weakly positive in the supplementary [ 18 F]-FDG PET/CT. Peptide receptor radionuclide therapy (PRRT) with [ 177 Lu]Lu-DOTA-octreotate, after longstanding efficacy with repetitive retreatments over 7 years, eventually resulted only in disease stabilization without partial regression of lesions. After switching PRRT to the somatostatin receptor antagonist [ 177 Lu]Lu-DOTA-LM3, a marked therapy response was observed, in remarkable contrast to the stable disease effect of 177 Lu-octreotate seen right before. This interesting image illustrates the superior therapeutic efficacy of somatostatin antagonist PRRT over agonist-based PRRT.
引用
- Speicher T, Burgard C, Rosar F, et al. Superior Response of CAP-PRRT of G3 NET When Switching to the Somatostatin Receptor Antagonist LM3: Intraindividual Proof-of-concept. Clin Nucl Med. 2025. PMID: 40302124. doi:10.1097/RLU.0000000000005938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。